Arca
Skip to content
Tools
Tools

Label Changes: Kybella (deoxycholic acid)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Kybella label DailyMed has published, from Kythera Biopharmaceuticals Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 19
  • Sections changed, version 25 to 26: 14

What changed from version 25 to version 26

Dec 31, 2025 to Sep 28, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 28 words added, 29 removed
  2. Dosage and administrationChanged · 338 words added, 351 removed
  3. Dosage forms and strengthsChanged · 14 words added, 31 removed
  4. ContraindicationsChanged · 5 words added, 6 removed
  5. Warnings and precautionsChanged · 418 words added, 265 removed
  6. Adverse reactionsChanged · 58 words added, 101 removed
  7. Use in specific populationsChanged · 32 words added, 91 removed
  8. DescriptionChanged · 57 words added, 66 removed
  9. Clinical pharmacologyChanged · 174 words added, 161 removed
  10. Nonclinical toxicologyChanged · 4 words added, 3 removed
  11. Clinical studiesChanged · 199 words added, 43 removed
  12. How suppliedChanged · 10 words added, 23 removed
  13. Patient counseling informationChanged · 53 words added, 33 removed
  14. Patient informationChanged · 248 words added, 159 removed

Indications and usage

Changed28 words added, 29 removed
1 INDICATIONS AND USAGE
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
Limitations of useU se
The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended [see Warnings and Precautions ( 5.5 )].

Dosage and administration

Changed338 words added, 351 removed
2 DOSAGE AND ADMINISTRATION
2.1 Dos age
2.1 Recommended Dos age
Before injection, see General Considerations for Administration [see Dosage and Administration ( 2.2 , 2.3 ) ] .
KYBELLA injection is injected into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm2.
Inject KYBELLA into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm2 (a single treatment of up to 100 mg (up to a total of 10 mL)) that consists of up to a maximum of 50 subcutaneous injections, (2 mg (0.2 mL)) each, spaced 1 cm apart.
A single treatment consists of up to a maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1 cm apart.
Up to 6 single treatments may be administered at intervals no less than 1 month apart.
See General Considerations for Administration ( 2.2 ) and Injection Technique ( 2.3 ) before injection.
2.2 General Considerations for Administration
2.2 Recommendations Prior to KYBELLA Treatment
KYBELLA should be administered by a healthcare professionalprovider.
Prior to KYBELLA treatment:
Screen patients for other potential causes of submental convexity/fullness (e.g., thyromegaly and cervical lymphadenopathy).
Give careful consideration toConsider the userisks of KYBELLA use in patients with excessive skin laxity, prominent platysmal bands or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome.
Visually inspect KYBELLA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter (KYBELLA is clear, colorless and free of particulate matter).
Use cautionGiven inthat patients who have had prior surgical or aesthetic treatment of the submental area. Changesmay have changes in anatomy/landmarks or the presence of scar tissue that may impact the ability of the health care provider to safely administer KYBELLA or to obtain the desired aesthetic result, use KYBELLA with caution in such patients.
KYBELLA is clear, colorless and free of particulate matter. Visually inspect KYBELLA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter.
After use, discard any remaining solution in the vial.
2. 3 Injection Technique
The safe and effective use of KYBELLA depends on the use of the correct number and locations for injections, proper needle placement, and administration techniques.
2. 3 Recommended Preparation and Administration Instructions
Healthcare professionals administering KYBELLA must understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures [ see W a r n in g s a n d Preca u ti o ns ( 5 ) ].
The safe and effective use of KYBELLA depends on the use of the correct number and locations of subcutaneous injections, proper needle placement, and administration technique. Prior to administration, understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures [ see W a r n in g s a n d Preca u ti o ns ( 5.1 ) ].
Avoid injections near the area of the marginal mandibular nerve
Avoid Injections Near the Area of the Marginal Mandibular Nerve
Needle placement with respect to the mandible is very important as it reduces the potential for injury to the marginal mandibular nerve, a motor branch of the facial nerve. Injury to the nerve presents as an asymmetrical smile due to paresis of lip depressor muscles [ see Warnings and Precautions ( 5.1 ) ].
To avoid injury to the marginal mandibular nerve:
Inject KYBELLA only within the target submental fat treatment area (see Figures 1 and 3).
Do not inject above the inferior border of the mandible.
Do not inject within a region defined by a 1-1.5 cm line below the inferior border (from the angle of the mandible to the mentum).
Inject KYBELLA only within the target submental fat treatment area (see Figures 1 and 3).
Figure 1. Avoid the Marginal Mandibular Nerve Area
Avoid injection into the platysma
Avoid Injection into the Platysma
Prior to each treatment session, palpate the submental area to ensure sufficient submental fat and to identify subcutaneous fat between the dermis and platysma (pre-platysmal fat) within the target treatment area (Figure 2). The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals.
Figure 2 . Sagittal View of Platy s ma Area
Injecting into the treatment area
Administration Instructions
UseConsider use of ice/cold packs, topical and/or injectable local anesthesia (e.g., lidocaine) mayto enhance patient comfort.
Outline the planned KYBELLA treatment area with a surgical pen and apply a 1 cm injection grid to mark the injection sites (Figures 2 andFigure 3).
Figure 3 . Treatment Area and Injection Pattern
Do not inject KYBELLA outside the defined parameters [see Warnings and Precautions ( 5.1 , 5.43 , 5.64 ) ]. and follow these subcutaneous administration instructions:
Using a large bore needle, draw 1 mL of KYBELLA into a sterile 1 mL syringe and expel any air bubbles in the syringe barrel.
Have the patient tense the platysma.
Have the patient tense the platysma. Pinch the submental fat and, using a 30 gauge (or smaller) 0.5 inch needle, inject 0.2 mL of KYBELLA into the pre-platysmal fat (see Figure 2) next to each of the marked injection sites by advancing the needle perpendicular to the skin.
Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis. Do not withdraw the needle from the subcutaneous fat during injection as this could increase the risk of intradermal exposure and potential skin ulceration and necrosis.
Do not withdraw the needle from the subcutaneous fat during injection; this could increase the risk of intradermal exposure and very superficial injections (into the dermis) may result in skin ulceration and necrosis [see Warnings and Precautions ( 5.3 )].
Avoid injecting into the post-platysmal fat by injecting KYBELLA into fat tissue at the depth of approximately mid-way into the subcutaneous fat layer (Figure 2).
If at any time resistance is met as the needle is inserted, indicating the possibility of contact with fascial or nonfat tissue, withdraw the needle must be withdrawn to an appropriate depth before the injection is administered.
Avoid injecting into other tissues such as the muscle, salivary glands, lymph nodes; and artery or vein [see Warnings and Precautions ( 5.4 )].
Upon needle withdrawal, pressure may beapply appliedpressure to each injection site as necessary to minimize bleeding; an adhesive dressing may be applied.
After use, discard any remaining solution in the vial. Do not dilute or mix KYBELLA with other compounds.

Dosage forms and strengths

Changed14 words added, 31 removed
3 DOSAGE FORMS AND STRENG T HS
Injection: 10 mg/mL.,
KYBELLA (deoxycholic acid) injection is a clear, colorless, sterile solution supplied in 2 mL vials intended for single patient use. Each milliliter of the solution contains 10 mg of deoxycholic acid.
clear, colorless, sterile solution supplied in 2 mL vials intended for single patient use.

Contraindications

Changed5 words added, 6 removed
4 CONTRAINDICATIONS
KYBELLA injection is contraindicated in thepatients presencewith ofan infection atin the injection sitesarea.

Warnings and precautions

Changed418 words added, 265 removed
5 WARNINGS AND PR E CAUTIONS
5 . 1 Marginal mandibular nerve injury
5. 1 Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA injection should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days).
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported in KYBELLA-treated patients during clinical trials. All marginal mandibular nerve injuries reported from the trials resolved without additional treatment (range 1-298 days, median 44 days).
To avoid the potential for marginal mandibular nerve injury, do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve [see Dosage and Administration ( 2.3 )].
5 . 2 Dysphagia
Difficulty swallowing (dysphagia) occurred in KYBELLA-treated patients in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved without additional treatment (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials.
Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition.
Avoid use of KYBELLA in patients with a current or prior history of dysphagia because KYBELLA use may exacerbate the condition.
5.3 Injection site hematoma /bruising
5.3 Injection Site Reactions
Injection Site Hematoma or Bruising
In clinical trials, 72% of subjects treated with KYBELLA experiencedhad an injection site hematoma/ or bruising [see Adverse Reactions ( 6.1 ) ].
KYBELLA should beUse usedKYBELLA with caution in patients with bleeding abnormalities or who are currently being treated(e.g., withtaking antiplatelet or anticoagulant therapy) as excessive bleeding or bruising in the treatment area may occur.
Injection Site Alopecia
Cases of injection site alopecia have been reported with KYBELLA administration. The onset and duration of this adverse reaction may vary among individuals and may persist.
Consider withholding subsequent KYBELLA treatments until resolution of this adverse reaction.
Injection Site Ulceration, Necrosis, Nodule, Mass, and Infection
Very superficial injections (into the dermis) of KYBELLA may result in skin ulceration and necrosis [see Dosage and Administration ( 2.3 )]. Cases of injection site ulceration, necrosis, nodule (≤ 3 cm in diameter), mass (> 3 cm in diameter), and infection have been reported with KYBELLA administration. Nodules or masses may occur following initial or subsequent KYBELLA administration. Some nodules and masses may not resolve and medical intervention may be required. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage.
Discontinue KYBELLA if patients develop injection site ulceration, necrosis, nodule, mass, or infection after KYBELLA administration.
5.4 Risk of injecting in proximity to vulnerable anatomic structure s
5.4 Risk of Injecting in Proximity to Vulnerable Anatomic Structures
To avoid potential tissue damage, KYBELLA shoulddo not beinject injectedKYBELLA into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
Care should be taken to avoidAvoid inadvertent injection directly into an artery or a vein as it can result in vascular injury.
5.5 Injection site alopecia
Cases of injection site alopecia have been reported with the administration of KYBELLA. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent treatments until resolution of the adverse reaction.
5.6 Injection site ulceration , necrosis , and infection
Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis [see Injection Technique ( 2.3 )]. Cases of injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Do not administer KYBELLA into the affected area until complete resolution of the adverse reaction.
5.5 Serious Adverse Reactions Associated with Unapproved Use Outside the Submental Region
Serious adverse reactions have been reported following unapproved administration of KYBELLA outside the submental region (e.g., blurred or reduced vision with periorbital use, muscle or nerve injury including facial paresis and paresthesia). Cases of injection site nodules (≤ 3 cm in diameter) and masses (> 3 cm in diameter) have also been reported following initial or subsequent administration of KYBELLA outside the submental region. The nodules and masses may not resolve and medical intervention may be required.
KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region [see Indications and Usage ( 1 )].

Adverse reactions

Changed58 words added, 101 removed
2 unchanged lines
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA injection and 506 subjects were treated with placebo. The population was 19-65 years old, 85% were women, 87% Caucasian, 8% African American. At baseline the population had a mean BMI of 29 kg/m2, moderate to severe submental convexity (graded as 2 or 3 on a 0 to 4 scale) and without excessive skin laxity. Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment.
In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA and 506 subjects were treated with placebo [see Clinical Studies ( 14 )]. Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment.
The most commonly reported adverse reactions are listed below (Table 1).
20 unchanged lines
a Adverse reactions that occurred in ≥ 2% KYBELLA treated subjects and at greater incidence than placebo b Marginal mandibular nerve paresis
Other adverse reactions associated with the use of KYBELLA include:included injection site hemorrhage, injection site discoloration, pre-syncope/syncope, lymphadenopathy, injection site urticaria, and neck pain.
Adverse reactions that lasted more than 30 days and occurred in more than 10% of KYBELLA-treated subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%).
6.2 Postmarketing Experience
1 unchanged line
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.
Administration siteSite conditionsConditions: injection site ulceration, necrosis, infectionmass, alopeciainfection, scarringalopecia, and massscarring.
Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching.
Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia.
Procedural Complications: Vascular injury due to inadvertent intravascular injection.

Use in specific populations

Changed32 words added, 91 removed
2 unchanged lines
Risk Summary
There are no adequate and well-controlled studiestrials of KYBELLA injection in pregnant women to inform the drug-associated risk. In animal reproduction studies, no fetal harm was observed with the subcutaneous administration of deoxycholic acid to rats during organogenesis at doses up to 5 times the maximum recommended human dose (MRHD) of 100 mg [see Data] .
The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects in the U.S. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
Data
Animal Data:
Embryofetal development studies have been performed in rats and rabbits using subcutaneous doses of deoxycholic acid administered during the period of organogenesis. For the basis of comparing animal to human doses, the MRHD is 1.7 mg/kg (100 mg/60 kg). No evidence of fetal harm was observed in rats at up to the highest dose tested (50 mg/kg) which is 5-fold higher than the MRHD of KYBELLA based on a mg/m2 comparison. However, missing intermediate lung lobe was noted in rabbits at all dose levels tested including the lowest dose (10 mg/kg) which is 2-fold higher than the MRHD of KYBELLA based on a mg/m2 comparison. These effects may be related to maternal toxicity, which was also seen at all dose levels tested.
3 unchanged lines
8 . 4 Ped i atr i c Use
Safety and effectiveness in patients below the age of 18 yearsKYBELLA have not been established in pediatric patients and KYBELLA is not intendedrecommended for use in children or adolescents.
8.5 Geriatric Use
The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.

Description

Changed57 words added, 66 removed
11 DESCRIPTION
KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use. It contains a cytolytic agent, deoxycholic acid, as the active ingredient. The chemical name of deoxycholic acid is 3α,12α-dihydroxy-5β-cholan-24-oic acid, and its molecular formula is C24H40O4, and its molecular weight is 392.57 g/mol. The chemical structure of deoxycholic acid is:
The chemical name of deoxycholic acid is 3α,12α-dihydroxy-5β-cholan-24-oic acid, and its molecular formula is C24H40O4, and its molecular weight is 392.57 g/mol. The chemical structure of deoxycholic acid is:
KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use. Each 2 mL vial of KYBELLA injection contains 20 mg syntheticof deoxycholic acid, a cytolytic agent, as the active ingredient and the following inactive ingredients: benzyl alcohol (18 mg), dibasic sodium phosphate (2.84 mg), sodium chloride (8.76 mg), sodium hydroxide (2.86 mg) in water for injection, USP. Hydrochloric acid and additional sodium hydroxide are added as necessary to adjust the formulation to pH 8.3. Each vial is for single patient use.

Clinical pharmacology

Changed174 words added, 161 removed
1 unchanged line
12.1 Mechanism of Action
KYBELLA injection is a cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis.
KYBELLA is a cytolytic drug, which when injected into submental fat - in patients with moderate to severe convexity or fullness associated with submental fat - physically destroys the cell membrane causing lysis.
1 2 .2 Phar m a c o d y n a mics
Cardiac Electrophysiology
At therapeutic doses, KYBELLA does not prolong the QTc interval.
At the recommended deoxycholic acid dose, clinically significant QTc interval prolongation was not observed.
1 2 .3 Phar m a c o k in et i cs
1 unchanged line
Absorption and Distribution
After KYBELLA subcutaneous injection, deoxycholic acid was rapidly absorbed. After dosing with the recommended single treatment KYBELLA dose (100 mg)
Maximum plasma concentrations of deoxycholic acid (mean Cmax) were observed with a median Tmax of 18 minutes after injection.
Mean (±SD) deoxycholic acid exposure (AUC0-24) was 7896 ± 2269 ng.hr/mL and was 1.6-fold higher over endogenous exposure.
Deoxycholic acid from KYBELLA is rapidly absorbed following subcutaneous injection. After dosing with the maximum recommended single treatment dose with KYBELLA (100 mg), maximum plasma concentrations (mean Cmax) were observed with a median Tmax of 18 minutes after injection. The mean (±SD) Cmax value was 1024 ± 304 ng/mL and was 3.2-fold higher than average Cmax values observed during a 24-hour baseline endogenous period in the absence of KYBELLA. After maximum recommended single treatment dose (100 mg), mean (±SD) deoxycholic acid exposure (AUC0-24) was 7896 ± 2269 ng.hr/mL and was 1.6-fold higher over endogenous exposure. Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours. No accumulation is expected with the proposed treatment frequency.
The mean (±SD) Cmax value was 1024 ± 304 ng/mL and was 3.2-fold higher than average Cmax values observed during a 24-hour baseline endogenous period in the absence of KYBELLA. Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours. No accumulation is expected with the proposed treatment frequency.
Deoxycholic acid is extensively bound to proteins in plasma (98%).
1 unchanged line
Endogenous deoxycholic acid is a product of cholesterol metabolism and is excreted intact in feces. Deoxycholic acid is not metabolized to any significant extent under normal conditions. Deoxycholic acid from KYBELLA joins the endogenous bile acid pool in the enterohepatic circulation and is excreted along with the endogenous deoxycholic acid.
Drug Interaction Studies
In Vitro Assessment of Drug Interactions :
Results from in vitro studies indicate that deoxycholic acid does not inhibit or induce human cytochrome P450 (CYP) enzymes at clinically relevant concentrations. Deoxycholic acid does not inhibit the following transporters: P-gp, BCRP, MRP4, MRP2, OATP1B1, OATP2B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, NTCP, and ASBT.
Specific Populations
Hepatic Impairment
Patients with Hepatic Impairment :
KYBELLA has not been studied in subjects with hepatic impairment. Considering the intermittent dose frequency, the small dose administered that represents approximately 3% of the total bile acid pool, and the highly variable endogenous deoxycholic acid levels, the pharmacokinetics of deoxycholic acid following KYBELLA injection is unlikely to be influenced by hepatic impairment.
Pharmacokinetic E ffects of Gender
Male and Female Patients: Deoxycholic acid pharmacokinetics were not influenced by gendersex.

Nonclinical toxicology

Changed4 words added, 3 removed
1 unchanged line
13.1 Carcinogenes i s, Mutagenes i s, Impairment of Fe r tility
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of KYBELLAdeoxycholic injectionacid.
KYBELLADeoxycholic acid was negative in a battery of in vitro (Ames test and chromosomal aberration assay in human lymphocytes) and in vivo (rat erythrocyte micronucleus assay) genetic toxicology assays.
No effects on fertility were observed in male and female rats administered deoxycholic acid at subcutaneous doses up to 50 mg/kg (5 times the MRHD based on a mg/m2 comparison) once weekly prior to and during the mating period and through gestation day 7 in female rats.

Clinical studies

Changed199 words added, 43 removed
14 CLINICAL STUDIES
Two randomized, multi-center, double-blind, placebo-controlled trials (Trials 1 and 2) of identical design were conducted to evaluate KYBELLA injection for use in improvementto inimprove the appearance of moderate to severe convexity or fullness associated with submental fat. The trials enrolled healthy adults (ages 19 to 65, BMI ≤ 40 kg/m2) with moderate or severe convexity or fullness associated with submental fat (i.e., grade 2 or 3 on 5-point grading scales, where 0 = none and 4 = extreme), as judged by both clinician and subject ratings. Subjects received up to 6 treatments with KYBELLA (N=514, combined trials) or placebo (N=508, combined trials) at no less than 1 month intervals. Use of ice/cold packs, topical and/or injectable local anesthesia was allowed during the clinical trials. Injection volume was 0.2 mL (2 mg) per injection site, spaced 1 cm apart into the submental fat tissue, which is also expressed in dose per area as 2 mg/cm2. For each treatment session a maximum of 100 mg (10 mL) was permitted over the entire treatment area. Subjects were administered an average of 64 mg (6.4 mL) at the first treatment session, and subjects who received all six treatments were administered an average of 44 mg (4.4 mL) at the sixth treatment session. Fifty-nineIn percentthese trials, 59% of subjects received all six treatments.
Baseline Demographics and Important Disease Characteristics
In these trials, the mean age was 49 years and the mean BMI was 29 kg/m2. Most of the subjects were women (85%) and CaucasianWhite (87%) and African American (8%). At baseline, 51% of the subjects had a clinician-rated submental fat severity rating of moderate submental fat rating (graded as 2 on a 0 to 4 scale) and 49% had a severe submental fat rating (graded as 3 on a 0 to 4 scale) and without excessive skin laxity.
Key Endpoints
The co-primary efficacy assessments in these trials were based on at least 2-grade and at least 1-grade improvements in submental convexity or fullness on the composite of clinician-reported and patient-reported ratings of submental fat 12 weeks after final treatment. Additionally, changes in submental fat volume were evaluated in a subset of subjects (N=449, combined trials) using magnetic resonance imaging (MRI). Visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were also evaluated using a 6-question survey, with each question rated from 0 (not at all) to 10 (extremely/very much).
Efficacy Results
ReductionsIn Trials 1 and 2, reductions in submental fat volume were observed more frequently in the KYBELLA group compared to the placebo group as measured by the composite clinician and patient ratings (Table 2). The composite response rates by visit are presented in Figure 4.
Table 2. ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response 12 Weeks After Final Treatment
Table 2. ≥ 2-Grade and ≥ 1-Grade Composite Clinician Response and Composite Patient Response 12 Weeks After Final Treatment in Adult Patients with Moderate to Severe Convexity or Fullness Associated with Submental Fat
| Trial 1 | Trial 2
3 unchanged lines
a At least 2 grade reduction on both the clinician-reported and patient-reported ratings of submental fat b At least 1 grade reduction on both the clinician-reported and patient-reported ratings of submental fat
Figure 4 . ≥ 2 -Grade and ≥ 1 -Grade Composite Clinician and Patient Response
Figure 4 . Subjects with ≥ 2 -Grade on Both the Clinician -Reporting Ratings and the Patient Response in Adult Patients with Moderate to Severe Convexity or Fullness Associated with Submental Fat
Note: Subjects were followed up 4, 12 and 24 weeks after the last¬ treatment. Forty-one percent of subjects received fewer than 6 treatments and entered the post-treatment period earlier than Week 24.
Figure 5 . Subjects with ≥ 1 -Grade on Both the Composite Clinician Response and the Composite Patient Response in Adult Patients with Moderate to Severe Convexity or Fullness Associated with Submental Fat
Subjects were followed up 4, 12 and 24 weeks after the last treatment. Forty-one percent of subjects received fewer than 6 treatments and entered the post-treatment period earlier than Week 24.
A greater proportion of KYBELLA-treated subjects had at least a 10% reduction in submental fat volume (evaluated by MRI) as compared to placebo-treated subjects when evaluated by MRI (43% vs 5%, respectively).
The overall patient-reported satisfaction and self-perceived visual attributes showed greater improvement in the KYBELLA group than in the placebo group.

How supplied

Changed10 words added, 23 removed
1 unchanged line
KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear, colorless, sterile solution supplied in 2 mL, single patient use vials in the following dispensing pack:
4 vials, NDC 61168-101-04
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].
KYBELLA has a unique hologram on the vial label. If you do not see a hologram, do not use the product and call 1-800-678633-16059110.
Each vial is for a single patient use. Do not dilute or mix KYBELLA with other compounds. Discard unused portion.
Each vial is for a single patient use.

Patient counseling information

Changed53 words added, 33 removed
1 unchanged line
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients to contact their healthcare providers if patients begin tothey develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), or difficulty swallowing, or worsening ofif existing symptoms worsen [see Warnings and Precautions ( 5.1 , 5.2 )].
Advise patients to contact their healthcare providers for development of erythema, pain, open sore(s) or drainage from the treatment area.
Distributed by: AbbVie Inc.
Advise patients to contact their healthcare providers if they develop injection site hematoma, brusing, alopecia, ulceration, necrosis, nodule, mass, infection, pain, numbness, induration, or paresthesia from the treatment area [see Warnings and Precautions ( 5.3 )].
Distributed by: AbbVie Inc. Manufactured for: AbbVie Inc. North Chicago, IL 60064 © 20242026 AbbVie. All rights reserved. KYBELLA® and its design are registered trademarks of Allergan Sales, LLC, an AbbVie company.
Patented. See www.abbvie.com/patents
v4V5.0USPI0101

Patient information

Changed248 words added, 159 removed
Patient Information KYBELLA ® (kye be lah) (deoxycholic acid ) injection
P ATIENT INFORMATION KYBELLA ® (kye be lah) (deoxycholic acid ) i njection for subcutaneous use
What is KYBELLA ? KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.” It is notThe knownuse ifof KYBELLA is safe and effective for the treatment of fat outside of the submental area is not recommended. It is not known if KYBELLA is safe and effective in children under 18 years of age.
Do not receive KYBELLA if you have an infection in the treatment area.
1 unchanged line
How will I receive KYBELLA ? KYBELLA is injected into the fat under your chin (up to 50 injections under your skin) by your healthcare provider. KYBELLA injections may be given at least 1 month apart. You and your healthcare provider will decide how many treatments you need.
What are the possible side effects of KYBELLA ? KYBELLA can cause serious side effects, including: Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness . Trouble swallowing . Injection site problems including: a collection of blood under the skin (hematoma) or bruising damage to an artery or vein if KYBELLA is inadvertently injected into it hair loss open sores (ulcers) damage and tissue cell-death (necrosis) around the injection site infection Call your healthcare provider if you: begin to develop weakness in the muscles of your face, or your smile becomes uneven you have difficulty swallowing, or if any of the symptoms that you already have get worse develop redness, pain, open sores, or drainage at or from the treatment area The most common side effects of KYBELLA include:
What are the possible side effects of KYBELLA ? KYBELLA can cause serious side effects, including: Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness . Trouble swallowing . Injection site problems including: a collection of blood under the skin (hematoma) or bruising damage to an artery or vein if KYBELLA is inadvertently injected into it hair loss open sores (ulcers) damage and tissue cell-death (necrosis) around the injection site nodules (≤ 3 cm in diameter) or mass (> 3 cm in diameter). Some nodules and masses may not resolve, and medical treatment, may be required. Infection KYBELLA can cause serious side effects when injected into areas of the body other than below the chin (submental area) including: blurred or reduced vision when injected around the eyes muscle or nerve damage, including numbness and tingling in the face lumps or nodules where the injection was given. These lumps or nodules may not resolve in time and medical treatment, may be required Call your healthcare provider if you: begin to develop weakness in the muscles of your face, or your smile becomes uneven you have difficulty swallowing, or if any of the symptoms that you already have get worse develop redness, pain, open sores, or drainage at or from the treatment area. The most common side effects of KYBELLA include:
● swelling | ● redness
●swelling pain numbness | ●redness areas of hardness in the treatment area
● numbness |
These are not all of the possible side effects of KYBELLA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
1 unchanged line
What are the ingredients in KYBELLA ? Active ingredient: deoxycholic acid Inactive ingredients: benzyl alcohol, dibasic sodium phosphate, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection, USP.
Distributed by: AbbVie Inc. Manufactured for: AbbVie Inc. North Chicago, IL 60064 © 20242026 AbbVie. All rights reserved. KYBELLA® and its design are registered trademarks of Allergan Sales, LLC, an AbbVie company. Patented. See www.abbvie.com/patents For more information about KYBELLA go to www.mykybella.com. |
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 1009/20242026
v4V5.0PPI0101

Unchanged: Package label.

Every version

19 versions of set fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.